



## Tanvex Reaches Settlement and License Agreement with Genentech

Feb. 09, 2023

Tanvex announced that the company has reached an agreement with Genentech to settle the patent litigation related to certain patents associated with Herceptin®. The legal action, which is pending in the U.S. District Court for the Southern District of California, will be dismissed as a result of the settlement. In addition to the United States, the licensed territory includes the other markets in which Genentech has obtained rights to the respective patents. All other terms of the agreement are confidential.

### **About Tanvex**

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biopharmaceutical market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.